Recurrence patterns and adjuvant therapy in endometrioid early-stage endometrial cancer with a p53-abnormal pattern
Abstract
ObjectiveCurrent guidelines recommend different adjuvant treatment strategies for women with endometrioid early-stage endometrial cancer exhibiting a p53-abnormal pattern. We aimed to evaluate recurrence patterns and explore the clinical implications for adjuvant therapy in this population.
Materials and methodsThis multicenter retrospective study included 86 patients with endometrioid, p53-abnormal, FIGO stage I-II endometrial cancer treated between 2013 and 2023 at six hospitals in the Republic of Korea. Clinicopathologic data were collected through medical record review. Progression-free survival (PFS) was estimated using the Kaplan- Meier method, and prognostic factors were analyzed using Cox proportional hazards regression models.
ResultsThe 12-, 24-, and 36-month PFS rates were 91%, 78%, and 76%, respectively. Among the 16 patients who experienced recurrence, 12 (75%) had distant metastases. Adjuvant chemotherapy showed a trend toward improved PFS compared with adjuvant radiation therapy with or without chemotherapy (p=0.10). In multivariable analysis, the p53-overexpression pattern was independently associated with worse PFS compared with the p53-null pattern (HR 8.59, 95% CI 1.61-45.79, p=0.01).
ConclusionGiven the poor PFS, the predominance of distant recurrence and the observed trend toward improved PFS with chemotherapy, adjuvant chemotherapy may be considered in women with endometrioid early-stage endometrial cancer exhibiting a p53-abnormal pattern. Further studies are warranted to clarify the prognostic impact of p53 abnormality subtypes.
Related
- Exploring patterns of acute and primary care utilisation before diagnosis, during treatment and for 3 years postcompletion of surgery and adjuvant treatment in women with endometrial cancer: a protocol for a Victorian data linkage study
- Comparing the Recurrence Patterns of Reduced-Margins vs. RTOG-Protocol in Adjuvant Chemoradiation of High-Grade Gliomas: A Multicenter, Open-Label, Randomized Controlled Trial
- Association of VCP/p97 Expression with Clinicopathological Features and Overall Survival in Endometrioid Endometrial Carcinoma
- Case Report: Primary endometrioid adenocarcinoma of the cervix and secondary cervical involvement by endometrial carcinoma: diagnostic pitfalls and an integrated approach based on two cases
- Metformin as an Adjunct to Fertility-Sparing Treatment in Atypical Endometrial Hyperplasia and Early-Stage Endometrioid Endometrial Cancer: Narrative Review.
BibTeX
@misc{lee2026recurrence,
title = {{Recurrence patterns and adjuvant therapy in endometrioid early-stage endometrial cancer with a p53-abnormal pattern}},
author = {S. h. Lee and P. D. Karimah and K. KIM and S. I. Kim and W. Y. Hwang and M. K. Kim and J.-H. Kim and C. H. Choi and Y.-K. Lee},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.14.26365577},
url = {https://www.medrxiv.org/content/10.64898/2026.10.14.26365577v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Recurrence patterns and adjuvant therapy in endometrioid early-stage endometrial cancer with a p53-abnormal pattern
AU - S. h. Lee
AU - P. D. Karimah
AU - K. KIM
AU - S. I. Kim
AU - W. Y. Hwang
AU - M. K. Kim
AU - J.-H. Kim
AU - C. H. Choi
AU - Y.-K. Lee
PY - 2026
DA - 2026/10/14
PB - medRxiv
DO - 10.64898/2026.10.14.26365577
UR - https://www.medrxiv.org/content/10.64898/2026.10.14.26365577v1
AB - ObjectiveCurrent guidelines recommend different adjuvant treatment strategies for women with endometrioid early-stage endometrial cancer exhibiting a p53-abnormal pattern. We aimed to evaluate recurrence patterns and explore the clinical implications for adjuvant therapy in this population. Materials and methodsThis multicenter retrospective study included 86 patients with endometrioid, p53-abnormal, FIGO stage I-II endometrial cancer treated between 2013 and 2023 at six hospitals in the Republic of Korea. Clinicopathologic data were collected through medical record review. Progression-free survival (PFS) was estimated using the Kaplan- Meier method, and prognostic factors were analyzed using Cox proportional hazards regression models. ResultsThe 12-, 24-, and 36-month PFS rates were 91%, 78%, and 76%, respectively. Among the 16 patients who experienced recurrence, 12 (75%) had distant metastases. Adjuvant chemotherapy showed a trend toward improved PFS compared with adjuvant radiation therapy with or without chemotherapy (p=0.10). In multivariable analysis, the p53-overexpression pattern was independently associated with worse PFS compared with the p53-null pattern (HR 8.59, 95% CI 1.61-45.79, p=0.01). ConclusionGiven the poor PFS, the predominance of distant recurrence and the observed trend toward improved PFS with chemotherapy, adjuvant chemotherapy may be considered in women with endometrioid early-stage endometrial cancer exhibiting a p53-abnormal pattern. Further studies are warranted to clarify the prognostic impact of p53 abnormality subtypes.
ER -